Castle Biosciences
CSTL
163 hedge funds and large institutions have $1.29B invested in Castle Biosciences in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 45 reducing their positions, and 19 closing their positions.
322% more capital inflows, than outflows
Capital inflows: $469M | Capital outflows: $111M
159% more call options, than puts
Call options by funds: $8.19M | Put options by funds: $3.16M
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
42% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 45
13% more funds holding
Funds holding: 144 → 163 (+19)
12.35% more ownership
Funds ownership: 68.35% → 80.7% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$87.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$56.1M |
| 3 |
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$54.2M |
| 4 |
Wasatch Advisors
Salt Lake City,
Utah
|
+$37.2M |
| 5 |
GW&K Investment Management
Boston,
Massachusetts
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nexpoint Asset Management
Dallas,
Texas
|
-$36.4M |
| 2 |
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$12.6M |
| 3 |
Granahan Investment Management
Waltham,
Massachusetts
|
-$7.64M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$4.47M |
| 5 |
Oxford Financial Group
Carmel,
Indiana
|
-$4.41M |
CSTL Hedge Fund Activity: Q4 2020 in Review
163 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2020, worth a combined $1.29B — up 86% from $692M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CSTL positions and 19 closed out — a net gain of 20 holders — while 64 added to existing stakes and 45 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $87.9M. The largest seller was Nexpoint Asset Management, exiting entirely with an estimated $36.4M sold.
- 163 institutional investors held Castle Biosciences (CSTL) as of Q4 2020, up from 144 in Q3 2020.
- Funds reported $1.29B of Castle Biosciences stock for Q4 2020, up 86% quarter-over-quarter.
- 39 funds opened new Castle Biosciences positions in Q4 2020 and 19 closed out, a net change of +20 holders.
- The largest Castle Biosciences buyer in Q4 2020 was ARK Investment Management, an estimated $87.9M added.
- The largest Castle Biosciences seller in Q4 2020 was Nexpoint Asset Management, an estimated $36.4M sold.
Based on aggregated 13F filings for Q4 2020.